News und Analysen
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that
First half results 2022/23: Growth in all regions and further progress on strategic initiatives
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
Approval of extension of exemptions from SIX disclosure and publicity obligations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
Sonova Investor & Analyst Day 2022: Leading innovation and further expanding our reach
Kapruvia® (Difelikefalin) jetzt in Deutschland für Hämodialysepatient:innen mit CKD-assoziiertem Pruritus erhältlich
CSL Vifor gab heute die Markteinführung von Kapruvia® zur Behandlung von mäßigem bis schwerem Juckreiz im Zusammenhang mit CKD bei Erwachsenen bekannt, die sich einer Hämodialyse unterziehen.1 Kapr
Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) hat heute die Zulassung von Tavneos® durch die Schweizerische Zulassungs- und Aufsichtsbehörde für Arzneimittel und Medizinprodukte Swissmedic
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic